Literature DB >> 30946543

Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence.

Chittaranjan Andrade1.   

Abstract

Clinical evidence is accumulating to support the use of ketamine as a powerful, quick-acting intervention for depression. Ketamine has been administered by oral, sublingual, transmucosal, intravenous, intramuscular, subcutaneous, intranasal, and even rectal routes. Whereas intravenous ketamine is the best studied approach, common sense dictates that oral ketamine is the most practical. The bioavailability of oral ketamine and interindividual variations thereof have been poorly studied; possibly only 20%-25% of an oral dose reaches the bloodstream. This is not necessarily a limitation because, as with other drugs that have poor oral bioavailability, compensation is possible by administering an appropriately higher dose, and interindividual variations can be addressed through individualized dose up-titration. A quarter- century of experience supports the use of oral ketamine for treating acute and chronic pain in children and adults. Case reports, case series, chart reviews, and 3 recent randomized controlled trials (RCTs) show that oral ketamine is effective in treating severe depression, depression with suicidal ideation, and treatment-resistant depression; that oral ketamine, used as an augmentation agent, improves outcomes in patients receiving a conventional antidepressant; and that oral ketamine reduces depression in patients with chronic pain. Doses of oral ketamine have ranged from 0.25 to 7 mg/kg and from 50 mg per occasion to 300 mg per occasion in multiple daily dosing, daily dosing, and intermittent dosing schedules. Oral ketamine was well tolerated in all studies; dropout and reasons for dropout were similar in ketamine and control arms in the 3 RCTs. These findings suggest that if ketamine is to find a place as an off-label treatment for depression and suicidality in mainstream psychiatry, researchers should study the safety, efficacy, and optimization of oral ketamine. Intravenous and intranasal routes may be monetarily more promising, but the oral route could be of greatest service. © Copyright 2019 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30946543     DOI: 10.4088/JCP.19f12820

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Efficacy of the Whole-Body Cryotherapy as Add-on Therapy to Pharmacological Treatment of Depression-A Randomized Controlled Trial.

Authors:  Joanna Rymaszewska; Katarzyna M Lion; Lilla Pawlik-Sobecka; Tomasz Pawłowski; Dorota Szcześniak; Elżbieta Trypka; Julia E Rymaszewska; Agnieszka Zabłocka; Bartlomiej Stanczykiewicz
Journal:  Front Psychiatry       Date:  2020-06-09       Impact factor: 4.157

Review 2.  Effects of somatic treatments on suicidal ideation and completed suicides.

Authors:  Elise M Hawkins; William Coryell; Stephen Leung; Sagar V Parikh; Cody Weston; Paul Nestadt; John I Nurnberger; Adam Kaplin; Anupama Kumar; Ali A Farooqui; Rif S El-Mallakh
Journal:  Brain Behav       Date:  2021-10-17       Impact factor: 2.708

3.  Repeated Yueju, But Not Fluoxetine, Induced Sustained Antidepressant Activity in a Mouse Model of Chronic Learned Helplessness: Involvement of CaMKII Signaling in the Hippocampus.

Authors:  Zhilu Zou; Jiaru Huang; Qingqing Yang; Yuxuan Zhang; Bo Xu; Ping Wang; Gang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-24       Impact factor: 2.629

4.  Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.

Authors:  Danika Dai; Courtney Miller; Violeta Valdivia; Brian Boyle; Paula Bolton; Shuang Li; Steve Seiner; Robert Meisner
Journal:  BMC Psychiatry       Date:  2022-02-22       Impact factor: 3.630

5.  Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use.

Authors:  Kazi Hassan; William M Struthers; Aditya Sankarabhotla; Patrick Davis
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.